DDrare: Database of Drug Development for Rare Diseases

Searched query = "Alagille syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 3 mg [14C]-A4250 capsule; A4250; CRC (A3384); Chloride; Eicosapentaenoic acid; LUM001; MARALIXIBAT CHLORIDE; Magnesium; Magnesium gluconate; Magnesium sulfate; Maralixibat; Maralixibat (formely SHP625 or LUM001); Maralixibat chloride; Phenylbutyrate; Questran; Sulfate

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041180088	01/12/2016	12/03/2019	Influence of fatty acid metabolism for clinical course of biliary atresia	The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia	biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.	oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid	Sumida Wataru	Uchida Hiroo	Recruiting	Not applicable	Not applicable	Both	30	N/A	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-jRCTs041180088

01/12/2016

12/03/2019

Influence of fatty acid metabolism for clinical course of biliary atresia

The difference of the profile of fatty acids and eicosanoids in clinical course and the effect to the prognosis by collection of biliary atresia

biliary atresia, neonatal hepatitis, Alagille syndrome, PFIC, etc.

oral administration of 30(+/- 10)mg/kg/day of eicosapentaenoic acid

Sumida Wataru

Uchida Hiroo

Recruiting

Not applicable

Both

N/A

Japan